AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts collectively rate AnaptysBio “Moderate Buy.” Of 16 firms, 12 recommend buying, three advise holding and one recommends selling; the average 12-month price target is $79.85.
• AnaptysBio reported a strong quarterly performance, posting $5.11 EPS versus analyst expectations for a $0.46 loss and revenue of $27.49 million versus the $14.06 million consensus estimate.
• The stock opened at $53.92, below its 50-day moving average of $55.67 and 200-day moving average of $59.22. Institutional investors have generally increased their positions, including First Light Asset Management and Squarepoint Ops.

Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the sixteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and twelve have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $79.8462.

Several research firms recently commented on ANAB. HC Wainwright reaffirmed a "buy" rating and issued a $95.00 price target on shares of AnaptysBio in a research note on Tuesday. Cantor Fitzgerald reissued an "overweight" rating on shares of AnaptysBio in a research report on Tuesday. Zacks Research lowered shares of AnaptysBio from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, June 2nd. Scotiabank lowered AnaptysBio to a "hold" rating and set a $70.00 price target for the company. in a report on Tuesday, August 25th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of AnaptysBio in a research note on Friday, August 7th.

AnaptysBio Stock Performance

Shares of NASDAQ ANAB opened at $53.92 on Wednesday. The business's 50 day moving average price is $55.67 and its 200-day moving average price is $59.22. AnaptysBio has a fifty-two week low of $13.81 and a fifty-two week high of $72.36. The company has a market cap of $1.60 billion, a price-to-earnings ratio of 10.04 and a beta of 0.71.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings data on Monday, September 21st. The biotechnology company reported $5.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.46) by $5.57. AnaptysBio had a return on equity of 112.00% and a net margin of 82.37%.The company had revenue of $27.49 million during the quarter, compared to analysts' expectations of $14.06 million. During the same quarter in the previous year, the business earned ($1.30) EPS. Sell-side analysts predict that AnaptysBio will post -2.06 earnings per share for the current year.

Institutional Investors Weigh In On AnaptysBio

Hedge funds have recently made changes to their positions in the company. First Light Asset Management LLC grew its position in shares of AnaptysBio by 2.9% during the 2nd quarter. First Light Asset Management LLC now owns 582,004 shares of the biotechnology company's stock worth $39,285,000 after buying an additional 16,573 shares in the last quarter. Squarepoint Ops LLC lifted its stake in AnaptysBio by 21.2% in the second quarter. Squarepoint Ops LLC now owns 324,446 shares of the biotechnology company's stock worth $21,900,000 after acquiring an additional 56,743 shares during the period. Arizona State Retirement System lifted its stake in AnaptysBio by 13.5% in the second quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company's stock worth $295,000 after acquiring an additional 518 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in AnaptysBio during the 2nd quarter worth about $1,164,000. Finally, Irenic Capital Management LP bought a new position in AnaptysBio during the 2nd quarter worth about $4,755,000.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company's programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio's pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.